Table 2.
Biologic plus methotrexate versus methotrexate for total X-ray score in rank order
| Medication | Reference | Follow-up period | Number | SMD (95% CI) |
|---|---|---|---|---|
| Infliximab | Lipsky et al13 | 54 weeks | 173 | −0.63 (−0.87 to −0.38) |
| Adalimumab | Keystone et al11 | 12 months | 299 | −0.45 (−0.68 to −0.22) |
| Breedveld et al14 | 12 months | 372 | −0.45 (−0.65 to −0.24) | |
| Pooled | −0.45 (−0.60 to −0.29) | |||
| Rituximab | Tak et al17 | 12 months | 443 | −0.46 (−0.65 to −0.28) |
| Cohen et al16 | 24 months | 468 | −0.41 (−0.59 to −0.22) | |
| Pooled | −0.44 (−0.58 to −0.30) | |||
| Etanercept | Emery et al7 | 12 months | 476 | −0.37 (−0.55 to −0.19) |
| Klareskog et al6 | 12 months | 430 | −0.36 (−0.55 to −0.17) | |
| Pooled | −0.37 (−0.50 to −0.23) | |||
| Certolizumab pegol | Smolen et al10 | 24 weeks | 373 | −0.29 (−0.51 to −0.08) |
| Abatacept | Kremer et al20 | 12 months | 586 | −0.21 (−0.39 to −0.04) |
| Westhovens et al21 | 12 months | 459 | −0.33 (−0.51 to −0.14) | |
| Pooled | −0.26 (−0.39 to −0.14) | |||
| Golimumab | Emery et al15 | 12 months | 541 | −0.09 (−0.26 to +0.08) |
Note: Bold text indicates pooled results for each agent.
Abbreviations: CI, confidence interval; SMD, standardized mean difference.